Navigation Links
First Commercially Cloned Dog Delivered to Florida Family
Date:1/28/2009

BioArts International announced today that they have delivered the world’s first commercially cloned dog, a 10-week old Labrador named Lancey, to Florida residents Edgar and Nina Otto.

Boca Raton, FL (Vocus) January 28, 2009 -- BioArts International announced today that they have delivered the world's first commercially cloned dog, a 10-week old Labrador named Lancey, to Florida residents Edgar and Nina Otto.

"We can't believe this day is finally here," said Nina Otto, "We are so happy to have little Lancey in our family. His predecessor was a very special dog. We are thrilled beyond words!"

Lancey was hand delivered to the Ottos on Monday, January 26th by BioArts Chairman Lou Hawthorne. "This is a very special milestone for our company – and great fun for me too," said Hawthorne, who delivered Lancey personally.

The Ottos were one of five families to bid and win an auction held by BioArts International in July for a chance to clone their family dog. Lancey's genetic donor, Sir Lancelot, died in January, 2008, and the Ottos had his DNA stored. By October, samples from the original dog were on their way to the Sooam Biotech Research Foundation in Seoul, South Korea, which provides cloning services to BioArts.

Lancey was born on November 18, 2008, and brought to the U.S. on January 25, 2009 after being weaned from his surrogate mother.

The Ottos, longtime residents of Boca Raton, have had many beloved dogs over the years, but Lancey's genetic donor was unique. "Sir Lancelot was the most human of any dog we’ve ever had," said Otto. "He was a prince among dogs."

Said Hawthorne, "One minute with Lancey and you know he's special. He's both extremely aware and very sweet. The Ottos are the first of six current clients to receive their clone. The next 6 months will be very exciting both for our clients and our staff."

Additional information about the Best Friends Again program and dog cloning is available at www.bestfriendsagain.com. More information about BioArts is available at www.bioarts.com.

BioArts International is a biotech company focused on unique, untapped markets in the global companion animal, stem cell and human genomics industries. The Best Friends Again program is a collaboration between BioArts and the Sooam Biotech Research Foundation in South Korea, home to the best and most experienced dog cloning team in the world.

BioArts has been granted the sole, worldwide license for the cloning of dogs, cats and endangered species. The license was granted by Start Licensing, Inc. and applies to the somatic cell nuclear transfer (SCNT) cloning patents developed at the Roslin Institute for the cloning of Dolly the sheep.

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1926124.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination
2. EngagementHealth(R) Among First in Nation To Be Early Adopter of the NCQAs New Wellness & Health Promotion Accreditation Program
3. First U.S. Supermarkets Launch Total Nutrition Scoring System
4. Worlds First Medical Identification Franchise Launches Nationally
5. Come On In, Says One of the Pros! The Neigel Center for Cosmetic & Laser Surgery Hosts Their First Annual Pre Super Bowl Open House!
6. Guams First Lady of Fitness Wants You to Look Good Without Clothes
7. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2009 Results
8. Nonin Medical, Inc. Makes History With the First Continua(TM) Certified Product
9. UCI behind worlds first embryonic stem cell study in humans
10. S.C. BlueCross Hosts Grand Opening of Its First Health Insurance Retail Store
11. First Study to Test Real-World Effects of Stun Gun Use Raises Questions about Safety
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First Commercially Cloned Dog Delivered to Florida Family
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... ... ... you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium in beautiful ... offered an opportunity to collaborate and network with healthcare colleagues across the United States. ... for a lively discussion on trends and issues that healthcare leaders will face in ...
(Date:3/28/2017)... California (PRWEB) , ... March 28, 2017 , ... Bacteria and fungi are probably not ... microorganisms are bad. In fact, including the right microorganisms in your diet can actually improve ... favorite foods. , This is the topic of a new peer-reviewed paper ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... Office (JPO) for the composition of matter of ... the treatment or prevention of fibrotic disorders, including ... retinopathy (Japanese Patent #: 6060071).  This patent includes ...
Breaking Medicine Technology: